Sacituzumab Govitecan receives positive CHMP opinion as 2L treatment for adult patients with metastatic triple-negative breast cancer Read more
CHMP advises approval for Bristol Myers Squibb’s Opdivo plus Yervoy with chemo for metastatic NSCLC Read more